Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Radiometal-labeled somatostatin analogs for applications in cancer imaging and therapy.

Lewis JS, Anderson CJ.

Methods Mol Biol. 2007;386:227-40. doi: 10.1007/978-1-59745-430-8_8. Review.

PMID:
18604948
2.

Tumor imaging and therapy using radiolabeled somatostatin analogues.

de Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP.

Acc Chem Res. 2009 Jul 21;42(7):873-80. doi: 10.1021/ar800188e.

PMID:
19445476
3.
4.

DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.

Li WP, Lewis JS, Kim J, Bugaj JE, Johnson MA, Erion JL, Anderson CJ.

Bioconjug Chem. 2002 Jul-Aug;13(4):721-8.

PMID:
12121126
5.

Experience with indium-111 and yttrium-90-labeled somatostatin analogs.

Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A, Dudczak R.

Curr Pharm Des. 2002;8(20):1781-807. Review.

PMID:
12171531
6.
7.

In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake.

Lewis JS, Srinivasan A, Schmidt MA, Anderson CJ.

Nucl Med Biol. 1999 Apr;26(3):267-73.

PMID:
10363797
8.

Somatostatin receptor PET imaging with Gallium-68 labeled peptides.

Win Z, Al-Nahhas A, Rubello D, Gross MD.

Q J Nucl Med Mol Imaging. 2007 Sep;51(3):244-50. Epub 2007 Apr 30. Review.

PMID:
17464267
9.

Somatostatin analogs and radiopeptides in cancer therapy.

Froidevaux S, Eberle AN.

Biopolymers. 2002;66(3):161-83. Review.

PMID:
12385036
10.

[Somatostatin receptor-based imaging and therapy of digestive endocrine tumors].

Illouz F, Sadoul JL, Rohmer V.

Ann Endocrinol (Paris). 2010 Sep;71 Suppl 1:S3-12. doi: 10.1016/S0003-4266(10)70002-0. Review. French.

PMID:
21237328
11.

Peptide receptor imaging and therapy.

Kwekkeboom D, Krenning EP, de Jong M.

J Nucl Med. 2000 Oct;41(10):1704-13. Review.

12.

Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator.

Sprague JE, Peng Y, Sun X, Weisman GR, Wong EH, Achilefu S, Anderson CJ.

Clin Cancer Res. 2004 Dec 15;10(24):8674-82.

13.

Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer.

Okarvi SM.

Cancer Treat Rev. 2008 Feb;34(1):13-26. Epub 2007 Sep 17. Review.

PMID:
17870245
14.

Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).

Shokeen M, Anderson CJ.

Acc Chem Res. 2009 Jul 21;42(7):832-41. doi: 10.1021/ar800255q.

15.

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP.

J Nucl Med. 2005 Jan;46 Suppl 1:62S-6S. Review.

16.

NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.

Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC, Wenger S, Reubi JC, Mäcke HR.

Bioconjug Chem. 2002 May-Jun;13(3):530-41.

PMID:
12009943
17.

Radiolabeled peptides in the diagnosis and therapy of oncological diseases.

Weiner RE, Thakur ML.

Appl Radiat Isot. 2002 Nov;57(5):749-63. Review.

PMID:
12433051
18.
20.

Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.

Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR.

Clin Cancer Res. 2005 Feb 1;11(3):1136-45.

Supplemental Content

Support Center